Europe In-vitro Colorectal Cancer Screening Tests Market Share was valued over USD 368.0 million in 2019 and is expected to witness 5.0% CAGR from 2019 to 2026.
Get more details on this report - Request Free Sample PDF
Advancement in colorectal cancer screening tests will accelerate the growth rate of in-vitro colorectal cancer screening test in Europe. The introduction of new technologies in clinical practice to diagnose and treat diseases has enforced positive outcomes in CRC screening. The European Union administrators have addressed the introduction of transnational and national population-wide screening programs as a priority for healthcare policy of individual states. The EU countries initially screened for colorectal cancer through fecal occult blood test (FOBT), however, with the advancement in screening techniques, colonoscopy is widely used in screening of colorectal cancer in European countries. However, the approach of individual countries to screening programs varies due to the difference in health insurance systems and budgets.
Increasing incidences of colon and rectal cancer will supplement the growth of in-vitro colorectal cancer screening tests in Europe. According to the WHO, around 471,000 new cases of colorectal cancer were recorded in the European region. The Council of European Union had issued recommendations for screening programs to serve as a basis for European guidelines for CRC screening. Factors such as changing lifestyles, rising awareness and improved access to medical devices have increased the disease diagnosis rate in the Euroepan region. Further, improved survival rate and reduction in the overall patient treatment will fuel the market growth.
Europe Market, By Test Type
Fecal occult blood test (FOBT) segment held over USD 310.5 million revenue size in 2019. The increased demand for FOBT test is due to its non-invasiveness and inexpensiveness compared to other test types. The FOBT segment is further classified into guaiac FOB stool test, Immuno-FOB agglutination, Lateral Flow Immuno-FOB test, and Immuno-FOB ELISA tests. The Immuno-FOB agglutination and Immuno-FOB ELISA tests are the largest market in FOBT tests. The improved clinical performance of these tests compels the market growth in the European region.
Europe Market, By Country
Germany in-vitro colorectal cancer screening tests market recorded approximately USD 50.0 million revenue size in 2019. The country has high incidence of bowel cancer. In 2012 approximately 28,500 women and 33,740 men were diagnosed with bowel cancer. The increasing use of screening tests for the prevention of bowel cancer, augment the rate of screening colonoscopy participation. Further, changing lifestyle and food consumption patterns will fuel industry growth. The National Cancer Plan offers bowel cancer screening as an advanced and organized screening program. The factors such as capability to spot precursors of colorectal cancer with potential to reduce incidence of colorectal cancer and mortality will propel the invitro colorectal cancer screening tests market in Germany.
Competitive Market Share
Some of the major industry players involved in Europe in-vitro colorectal cancer screening tests market include Abbott Laboratories, Beckman Coulter Diagnostics, Epigenomics Ag Corporation, EMD Millipore, among other market players. The market for in-vitro colorectal cancer screening tests is highly fragmented with the firms focusing on rigourus expansion strategies to develop advanced tests capable of delivering accurate results instantly. For instance, in 2017, Siemens Healthineers expanded the diagnostics portfolio by acquiring NEO New Oncology AG, Germany. The strategy aimed at using company's cancer genome diagnostics- NEO to support oncologists and pathologists with molecular data to help in selecting targeted cancer therapies
Europe In-vitro Colorectal Cancer Screening Tests Industry Background
Evolution of in-vitro colorectal cancer screening industry began during the 2000s. In the 1980s and 1990s, FOBT and sigmoidoscopy were the most used screening tests for colorectal cancer. However, since 2000, most colorectal screening tests in Europe shifted towards colonoscopy. The recent data examining the incidence of colorectal cancer has observed a significant drop in the mortaility rate with the introduction of these screening programs. Endoscopic and FOBT testing methods are the major screening approaches adopted for identifying the presence of colorectal cancer. Expansion of clinically valuable fecal DNA test, assays with improved diagnostic sensitivity, and the identification of specific and broadly informative molecular markers are among the few technological advancement in the market. However, increasing incidence of colon and rectal cancer, growing longevity coupled with lifestyle changes such as lack of physical exercise and poor diet fuel the market growth in the forthcoming years.